A high-throughput metabolomics method to predict high concentration cytotoxicity of drugs from low concentration profiles
- 673 Downloads
A major source of drug attrition in pharmacological development is drug toxicity, which eventually manifests itself in detrimental physiological effects. These effects can be assessed in large sample cohorts, but generating rich sets of output variables that are necessary to predict toxicity from lower drug dosages is problematic. Currently the throughput of methods that enable multi-parametric cellular readouts over many drugs and large ranges of concentrations is limited. Since metabolism is at the core of drug toxicity, we develop here a high-throughput intracellular metabolomics platform for relative measurement of 50–100 targeted metabolites by flow injection-tandem mass spectrometry. Specifically we focused on central metabolism of the yeast Saccharomyces cerevisiae because potential cytotoxic effects of drugs can be expected to affect this ubiquitous core network. By machine learning based on intracellular metabolite responses to 41 drugs that were administered at seven concentrations over three orders of magnitude, we demonstrate prediction of cytotoxicity in yeast from intracellular metabolome patterns obtained at much lower drug concentrations that exert no physiological toxicity. Furthermore, the 13C-determined intracellular response of metabolic fluxes to drug treatment demonstrates the functional performance of the network to be rather robust, until growth was compromised. Thus we provide evidence that phenotypic robustness to drug challenges is achieved by a flexible make-up of the metabolome.
KeywordsYeast metabolism Drug enzyme interaction Off-target drug effects Metabolomics Method Machine-learning
S.H. gratefully acknowledges funding by Marie Curie Intra-European Fellowships (F6P-2005).
- Blank, L. M., Kuepfer, L., & Sauer, U. (2005). Large-scale 13C-flux analysis reveals mechanistic principles of metabolic network robustness to null mutations in yeast. Genome Biology, 6(6), R49.Google Scholar
- Committee on Toxicity Testing and Assessment of Environmental Agents, N. R. C. (2007). Toxicity Testing in the 21st Century: A vision and a strategy. Washington, DC: The National Academies Press.Google Scholar
- Turner, S. M., & Hellerstein, M. K. (2005). Emerging applications of kinetic biomarkers in preclinical and clinical drug development. Current Opinion in Drug Discovery & Development, 8(1), 115–126.Google Scholar